Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.

Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, Kim ND, Look T, Mitsiades CS, Weng AP, Brown JR, Benes CH, Marto JA, Young RA, Gray NS.

Nature. 2014 Jun 22. doi: 10.1038/nature13393. [Epub ahead of print]

PMID:
25043025
[PubMed - as supplied by publisher]
2.

Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.

Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C, Toner M, Maheswaran S, Haber DA.

Science. 2014 Jul 11;345(6193):216-20. doi: 10.1126/science.1253533.

PMID:
25013076
[PubMed - in process]
3.

CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers.

Heilmann AM, Perera RM, Ecker V, Nicolay BN, Bardeesy N, Benes CH, Dyson NJ.

Cancer Res. 2014 Jul 15;74(14):3947-58. doi: 10.1158/0008-5472.CAN-13-2923. Epub 2014 Jul 1.

PMID:
24986516
[PubMed - in process]
4.

EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.

Wang M, Kern AM, Hülskötter M, Greninger P, Singh A, Pan Y, Chowdhury D, Krause M, Baumann M, Benes CH, Efstathiou JA, Settleman J, Willers H.

Cancer Res. 2014 May 15;74(10):2825-34. doi: 10.1158/0008-5472.CAN-13-3157. Epub 2014 Mar 19.

PMID:
24648348
[PubMed - in process]
5.

Metadata Standard and Data Exchange Specifications to Describe, Model, and Integrate Complex and Diverse High-Throughput Screening Data from the Library of Integrated Network-based Cellular Signatures (LINCS).

Vempati UD, Chung C, Mader C, Koleti A, Datar N, Vidović D, Wrobel D, Erickson S, Muhlich JL, Berriz G, Benes CH, Subramanian A, Pillai A, Shamu CE, Schürer SC.

J Biomol Screen. 2014 Feb 11;19(5):803-816. [Epub ahead of print]

PMID:
24518066
[PubMed - as supplied by publisher]
6.

EMT twists the road to PI3K.

Niederst MJ, Benes CH.

Cancer Discov. 2014 Feb;4(2):149-51. doi: 10.1158/2159-8290.CD-13-1030.

PMID:
24501304
[PubMed - in process]
7.

Rotavirus gastroenteritis in the Czech Republic before the start of vaccination.

Pazdiora P, Beneš Č.

Epidemiol Mikrobiol Imunol. 2013 Dec;62(4):131-7.

PMID:
24467174
[PubMed - in process]
8.

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M, Benes CH, Engelman JA.

Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21124-9. doi: 10.1073/pnas.1314124110. Epub 2013 Dec 10.

PMID:
24327733
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, Rivera MN, Ramaswamy S, Hung KE, Benes CH, Engelman JA.

Cancer Discov. 2014 Jan;4(1):42-52. doi: 10.1158/2159-8290.CD-13-0315. Epub 2013 Oct 25.

PMID:
24163374
[PubMed - in process]
Free PMC Article
10.

Spatial distribution of a population at risk: an important factor for understanding the recent rise in tick-borne diseases (Lyme borreliosis and tick-borne encephalitis in the Czech Republic).

Zeman P, Benes C.

Ticks Tick Borne Dis. 2013 Dec;4(6):522-30. doi: 10.1016/j.ttbdis.2013.07.003. Epub 2013 Oct 16.

PMID:
24139627
[PubMed - in process]
11.

Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.

Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, Benes C, Hagen FK, Munger J, Crooks PA, Becker MW, Jordan CT.

J Biol Chem. 2013 Nov 22;288(47):33542-58. doi: 10.1074/jbc.M113.511170. Epub 2013 Oct 2.

PMID:
24089526
[PubMed - indexed for MEDLINE]
12.

EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.

Pfäffle HN, Wang M, Gheorghiu L, Ferraiolo N, Greninger P, Borgmann K, Settleman J, Benes CH, Sequist LV, Zou L, Willers H.

Cancer Res. 2013 Oct 15;73(20):6254-63. doi: 10.1158/0008-5472.CAN-13-0044. Epub 2013 Aug 21.

PMID:
23966292
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Whole chromosome instability resulting from the synergistic effects of pRB and p53 inactivation.

Manning AL, Benes C, Dyson NJ.

Oncogene. 2014 May 8;33(19):2487-94. doi: 10.1038/onc.2013.201. Epub 2013 Jun 24.

PMID:
23792446
[PubMed - indexed for MEDLINE]
14.

Differential determinants of cancer cell insensitivity to antimitotic drugs discriminated by a one-step cell imaging assay.

Tang Y, Xie T, Florian S, Moerke N, Shamu C, Benes C, Mitchison TJ.

J Biomol Screen. 2013 Oct;18(9):1062-71. doi: 10.1177/1087057113493804. Epub 2013 Jun 20.

PMID:
23788527
[PubMed - indexed for MEDLINE]
15.

[Differences in the incidence of viral hepatitis A and E in the Czech Republic].

Trmal J, Beneš C, Trnková M.

Epidemiol Mikrobiol Imunol. 2013 Apr;62(1):19-25. Czech.

PMID:
23768091
[PubMed - indexed for MEDLINE]
16.

[Incidence of tick-borne encephalitis in the czech republic in 2001-2011 in different administrative regions and municipalities with extended power].

Kříž B, Beneš C, Daniel M, Malý M.

Epidemiol Mikrobiol Imunol. 2013 Apr;62(1):9-18. Czech.

PMID:
23768090
[PubMed - indexed for MEDLINE]
17.

Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties.

Menden MP, Iorio F, Garnett M, McDermott U, Benes CH, Ballester PJ, Saez-Rodriguez J.

PLoS One. 2013 Apr 30;8(4):e61318. doi: 10.1371/journal.pone.0061318. Print 2013.

PMID:
23646105
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.

Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS.

Oncogene. 2014 Mar 20;33(12):1590-600. doi: 10.1038/onc.2013.92. Epub 2013 Apr 1.

PMID:
23542178
[PubMed - indexed for MEDLINE]
19.

Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics.

Chen L, Stuart L, Ohsumi TK, Burgess S, Varshney GK, Dastur A, Borowsky M, Benes C, Lacy-Hulbert A, Schmidt EV.

BMC Cancer. 2013 Feb 27;13:93. doi: 10.1186/1471-2407-13-93.

PMID:
23442791
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K.

Cancer Discov. 2013 Mar;3(3):308-23. doi: 10.1158/2159-8290.CD-12-0418. Epub 2013 Feb 21.

PMID:
23430699
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk